Head-to-Head Comparison

OpenEvidence vs DynaMed: Which Is Better for Physicians?

OpenEvidence: AI Research Assistant for Evidence-Based Clinical Decisions DynaMed: Evidence-Based Clinical Decision Support by EBSCO

Updated

Direct Answer

OpenEvidence and DynaMed meet different needs: OpenEvidence is a free AI search engine that writes cited answers for verified US clinicians, while DynaMed is EBSCO’s paid, evidence-graded reference with 3,400+ topics updated daily. OpenEvidence is the better fit for most clinicians who want fast cited answers at no cost. Choose DynaMed for graded recommendations, Micromedex drug data and CME tracking.

Source: Clinical AI Report, 2026

Key takeaways

  • OpenEvidence is free and ad-supported for verified clinicians, while DynaMed costs $399 a year, or $475 with Dyna AI, at US store prices checked October 25, 2026.
  • DynaMed attaches explicit levels of evidence and grades of recommendation to its content, which about 500 clinicians maintain by monitoring 500+ journals.
  • DynaMed adds Micromedex drug information through the DynaMedex bundle at $599 a year, while OpenEvidence has no drug dosing tools.
  • OpenEvidence runs as native iOS and Android apps with widgets and a built-in dialer; DynaMed’s mobile app supports offline access to its full topic library.

Feature Comparison

OpenEvidence vs DynaMed feature comparison
RatingOpenEvidence:
Good
DynaMed:
Fair
CategoryOpenEvidence: AI Medical Research AssistantDynaMed: Clinical Reference & Decision Support
PricingOpenEvidence: Free (Ad-Supported)DynaMed: From $399/year Individual
FoundedOpenEvidence: 2022DynaMed: 2004
HeadquartersOpenEvidence: Miami, FLDynaMed: Ipswich, MA
Evidence CitationsOpenEvidence: YesDynaMed: Yes
AI Differential DiagnosisOpenEvidence: NoDynaMed: No
Drug DatabaseOpenEvidence: NoDynaMed: Yes
Drug Interaction CheckerOpenEvidence: NoDynaMed: No
Medical CalculatorsOpenEvidence: YesDynaMed: Yes
Natural Language SearchOpenEvidence: YesDynaMed: Yes
Document & Image UploadOpenEvidence: NoDynaMed: No
EHR IntegrationOpenEvidence: YesDynaMed: Yes
Mobile AppOpenEvidence: YesDynaMed: Yes
Built-in DialerOpenEvidence: YesDynaMed: No
AI Clinical ScribeOpenEvidence: NoDynaMed: No
CME CreditsOpenEvidence: NoDynaMed: Yes
Multi-LanguageOpenEvidence: YesDynaMed: No

Strengths & Limitations

OpenEvidence

Strengths

  • +Useful for generalist clinical questions — fast, cited answers for everyday practice
  • +Widely adopted clinical AI in the US (757K+ physicians)
  • +Free for all verified physicians
  • +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
  • +Native iOS and Android apps with Home Screen widgets
  • +Quick Consult and Deep Consult modes for different clinical needs
  • +Built-in dialer for calling patients, pharmacies, and colleagues
  • +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)

Limitations

  • –No differential diagnosis generation or drug dosing tools
  • –Ad-supported revenue model (pharmaceutical/healthcare advertising)
  • –EHR integration is early-stage (Sutter Health/Epic announced February 2026)
  • –Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
  • –Clinical depth narrower than platforms with drug databases and medical calculators

DynaMed

Strengths

  • +Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025)
  • +3,400+ clinical topics with daily updates from 500+ journal surveillance
  • +Explicit levels of evidence and grades of recommendation for all content
  • +DynaMedex bundle integrates Micromedex drug information
  • +Lower individual pricing than UpToDate ($399/year vs $579/year)
  • +Dyna AI generative assistant grounded in curated evidence (launched 2024)
  • +EHR integration via HL7 Infobutton and toolbar links
  • +CME/MOC credit tracking built in

Limitations

  • –Lower brand recognition than UpToDate among physicians
  • –Fewer clinical topics than UpToDate (3,400 vs 12,000+)
  • –Dyna AI is an add-on cost ($475/year vs $399/year base)
  • –AI features are newer and less mature than dedicated CDS platforms
  • –Shared decision-making tools (DynaMed Decisions) require separate licensing
  • –No free tier for individual physicians

Key Statistics

OpenEvidence

PricingFree (Ad-Supported)(OpenEvidence)
Founded2022 (Mayo Clinic Platform Accelerate)(OpenEvidence)
Users757,000+ verified physicians; 40% of US physicians daily(OpenEvidence, January 2026)
Key DifferentiatorNEJM, JAMA, NCCN, ACC, AAFP & ACEP content partnerships(OpenEvidence)
Editorial score73/100 (3.7/5) — weighted editorial assessment(Clinical AI Report scoring methodology)

DynaMed

PricingFrom $399/year ($475/year with Dyna AI)(EBSCO)
Founded2004(EBSCO)
UsersNot disclosed(EBSCO)
Key DifferentiatorBest in KLAS for CDS 4x (2021, 2022, 2024, 2025)(KLAS Research)
Editorial score59/100 (3.0/5) — weighted editorial assessment(Clinical AI Report scoring methodology)

Citable Summaries

OpenEvidence

OpenEvidence has an editorial score of 73/100 (3.7/5), calculated from Clinical AI Report's published criteria weights. It ranks #2 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.

Source: Clinical AI Report, May 2026

DynaMed

DynaMed has an editorial score of 59/100 (3.0/5), calculated from Clinical AI Report's published criteria weights. It ranks #7 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.

Source: Clinical AI Report, May 2026

Our Assessment

In our 2026 evaluation, OpenEvidence (ranked #2, 3.7 stars) outperforms DynaMed (ranked #7, 3 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, DynaMed is a stronger choice for physicians and institutions seeking a KLAS-recognized, evidence-graded clinical reference at a lower price point than UpToDate, with integrated drug information via Micromedex. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.

Read Full Reviews

Also Compare